Managers / Q4 2020 · view latest →
ISZO CAPITAL MANAGEMENT LP
CIK 0001607925 · 590 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10022 · 646-775-4394
Summary
Iszo Capital Management LP reported $96M in U.S.-listed holdings across 6 positions for Q4 2020.
The portfolio is heavily concentrated: Avid Bioservices alone accounts for 28.7% of reported value.
Compared with Q3 2020, the fund opened 3 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 74.6% · $71M
- Other · 25.4% · $24M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| DMTKQDERMTECH INC | NEW | +475.0K | 475.0K | +$15M | $15M |
| ATEXANTERIX INC | NEW | +340.7K | 340.7K | +$13M | $13M |
| BIOANALYTICAL SYS INC | NEW | +760.0K | 760.0K | +$9M | $9M |
| WLLWHITING PETE CORP NEW | SOLD OUT | −77.0K | 0 | −$1M | $0 |
| CHICOS FAS INC | SOLD OUT | −39.9K | 0 | −$39,000 | $0 |
| XPELXPEL INC | TRIMMED | −270.2K | 121.4K | −$4M | $6M |
| AVID BIOSERVICES INC | TRIMMED | −1.08M | 2.38M | +$1M | $27M |
| NAM TAI PPTY INC | ADDED | +260.3K | 4.15M | −$12M | $24M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | AVID BIOSERVICES INC | COM | 28.70% | $27M | 2.38M |
| 2 | NAM TAI PPTY INC | SHS | 25.42% | $24M | 4.15M |
| 3 | DMTKQDERMTECH INChistory → | COM | 16.13% | $15M | 475.0K |
| 4 | ATEXANTERIX INChistory → | COM | 13.41% | $13M | 340.7K |
| 5 | BIOANALYTICAL SYS INC | COM | 9.78% | $9M | 760.0K |
| 6 | XPELXPEL INChistory → | COM | 6.55% | $6M | 121.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $2M | 1 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $2M | 3 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $18M | 3 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $19M | 10 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $7M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $58M | 6 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $64M | 6 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $84M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $190M | 7 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $227M | 7 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $275M | 8 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $212M | 5 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $96M | 6 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 5 | Nov 17, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $57M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $65M | 10 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $69M | 3 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $76M | 4 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $64M | 2 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $61M | 5 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $92M | 5 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.